Zobrazeno 1 - 10 of 21 pro vyhledávání: '"M. C. Graham"'
1
The Assessment and Remediation of Chromite Ore Processing Residue at Former Disposal Sites, Glasgow, Scotland: Current Status (2007)
Autor: Stephen Hillier, D. G. Lumsdon, J. G. Farmer, M. C. Graham, R. J. F. Bewley
Publikováno v: GeoCongress 2008.
Analytical, experimental and modelling work has identified the mineral phases and processes responsible for the retention and release of hexavalent chromium (Cr(VI)) from high-lime chromite ore processing residue (COPR) under prevailing field conditi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f69a8195559b1ee533c8623d524a5ad3
https://doi.org/10.1061/40970(309)93
Zobrazit plný text záznamu
2
Development of an ombrotrophic peat bog (low ash) reference material for the determination of elemental concentrations
Autor: C. Yafa, J. G. Farmer, M. C. Graham, J. R. Bacon, C. Barbante, W. R. L. Cairns, R. Bindler, I. Renberg, A. Cheburkin, H. Emons, M. J. Handley, S. A. Norton, M. Krachler, W. Shotyk, X. D. Li, A. Martinez-Cortizas, I. D. Pulford, V. MacIver, J. Schweyer
Publikováno v: Journal of environmental monitoring
6 (2004): 493–501.
info:cnr-pdr/source/autori:C. Yafa, J. G. Farmer, M. C. Graham, J. R. Bacon, C. Barbante, W. R. L. Cairns, R. Bindler, I. Renberg, A. Cheburkin, H. Emons, M. J. Handley, S. A. Norton, M. Krachler, W. Shotyk, X. D. Li, A. Martinez-Cortizas, I. D. Pulford, V. MacIver, J. Schweyer, E./titolo:Development of an ombrotrophic peat bog (low ash) reference material for the determination of elemental concentrations./doi:/rivista:Journal of environmental monitoring (Print)/anno:2004/pagina_da:493/pagina_a:501/intervallo_pagine:493–501/volume:6
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::47f20a9213a602397f86d2350d1904a1
http://www.cnr.it/prodotto/i/20016
Zobrazit plný text záznamu
3
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer
Autor: M C, Graham, H I, Scher, G B, Liu, S D, Yeh, T, Curley, F, Daghighian, S J, Goldsmith, S M, Larson
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(6)
Rhenium-186 (tin)-labeled hydroxyethylidene diphosphonate (186Re-labeled HEDP) was evaluated in 27 men with progressive androgen-independent prostate cancer and bone metastases. Administered activities ranged from 1251 to 4336 MBq (33.8-117.2 mCi). T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bea91328763a1dffb5d66c792a9d77eb
https://pubmed.ncbi.nlm.nih.gov/10389913
Zobrazit plný text záznamu
5
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
Autor: C R, Divgi, N H, Bander, A M, Scott, J A, O'Donoghue, G, Sgouros, S, Welt, R D, Finn, F, Morrissey, P, Capitelli, J M, Williams, D, Deland, A, Nakhre, E, Oosterwijk, S, Gulec, M C, Graham, S M, Larson, L J, Old
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 4(11)
This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic potential of 131I-G250. Thirty-three patients with measurable metastatic renal cell carcinoma were treated. Groups of at least thre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9ddd0f615fa6e34d12d5a10e0099f98d
https://pubmed.ncbi.nlm.nih.gov/9829736
Zobrazit plný text záznamu
7
Quantitative imaging of iodine-124 with PET
Autor: K S, Pentlow, M C, Graham, R M, Lambrecht, F, Daghighian, S L, Bacharach, B, Bendriem, R D, Finn, K, Jordan, H, Kalaigian, J S, Karp, W R, Robeson, S M, Larson
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 37(9)
PET is potentially very useful for the accurate in vivo quantitation of time-varying biological distributions of radiolabeled antibodies over several days. The short half-lives of most commonly used positron-emitting nuclides make them unsuitable for
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::914d6d92b3974bb71d9793159d84317d
https://pubmed.ncbi.nlm.nih.gov/8790218
Zobrazit plný text záznamu
8
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia
Autor: P C, Caron, M A, Schwartz, M S, Co, C, Queen, R D, Finn, M C, Graham, C R, Divgi, S M, Larson, D A, Scheinberg
Publikováno v: Cancer. 73
Long-term survival rates of patients with acute myelogenous leukemia treated with intensive chemotherapy are 15-20%, despite efforts to develop new treatment strategies. Murine M195 (131I-M195), an anti-CD33, immunoglobulin (Ig) G2a monoclonal antibo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5e545f9d5fbdffd7cbc7edb409b4d117
https://pubmed.ncbi.nlm.nih.gov/8306247
Zobrazit plný text záznamu
9
Three-dimensional dosimetry for radioimmunotherapy treatment planning
Autor: G, Sgouros, S, Chiu, K S, Pentlow, L J, Brewster, H, Kalaigian, B, Baldwin, F, Daghighian, M C, Graham, S M, Larson, R, Mohan
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 34(9)
Absorbed-dose calculations for radioimmunotherapy are generally based on tracer imaging studies of the labeled antibody. Such calculations yield estimates of the average dose to normal and target tissues assuming idealized geometries for both the rad
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::13a9f1723a4c433eba01fc3e206f7d00
https://pubmed.ncbi.nlm.nih.gov/8394886
Zobrazit plný text záznamu
10
Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia
Autor: G, Sgouros, M C, Graham, C R, Divgi, S M, Larson, D A, Scheinberg
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 34(3)
Individual patient response to radioimmunotherapy is influenced by each patient's tumor burden, antibody clearance kinetics and the antibody-antigen interaction. In hematologic malignancies, wherein antibody access to tumor-cell associated antigen is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c86d0710017d8ccb513261483f09ed95
https://pubmed.ncbi.nlm.nih.gov/8441034
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje